Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The findings were shared through one oral and two poster sessions, highlighting the potential of these candidates in cancer treatment.
TNX-1700, a novel biologic, showed promise in reducing inflammation and tumor progression in gastric cancer models. The data also demonstrated favorable pharmacokinetics, supporting its further development. Gastric cancer remains a significant unmet medical need, and these findings suggest TNX-1700 could offer a new therapeutic approach.
TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), exhibited promising in vitro activity, underscoring its potential as a cancer immunotherapy candidate. The data suggest TNX-4700 could be effective alone or in combination with other checkpoint inhibitors, potentially expanding treatment options for patients.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company's recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports marketed products including Zembrace SymTouch and Tosymra for acute migraine. The company is also advancing Phase 2 clinical trials evaluating TONMYA for major depressive disorder and acute stress disorder.
In addition to its immuno-oncology pipeline, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. TNX-2900 is Phase 2 ready for Prader-Willi syndrome, a rare disease.
The presentation of these data at AACR 2026 highlights Tonix's commitment to addressing high unmet medical needs in oncology. The company continues to leverage its expertise in immunology to develop innovative therapies.
For more information, visit https://ibn.fm/Oly6o and the company's newsroom at https://ibn.fm/TNXP.
